Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Therapeutics Reports Third Quarter Financial Results
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2018 . "We are pleased that our sitravatinib and MRTX849 (KRAS) programs are advancing into the
View HTML
Toggle Summary Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting
- Preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib and nivolumab in NSCLC patients will be presented in an oral presentation - Updated data from the ongoing Phase 2 clinical trial of mocetinostat and durvalumab in NSCLC patients will be presented in an oral
View HTML
Toggle Summary Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer
SAN DIEGO , Oct. 30, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration ( FDA ) to initiate a Phase 1/2 trial with
View HTML
Toggle Summary Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial
- Updated analysis from ongoing Phase 2 trial of sitravatinib in combination with nivolumab demonstrated significant clinical activity in patients with checkpoint refractory non-small cell lung cancer (NSCLC) - 16 partial or complete responses observed in first 56 evaluable patients - Tumor
View HTML
Toggle Summary Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress
- Clinical data in non-small cell lung cancer (NSCLC) and melanoma patients with CBL inactivating mutations treated with single agent sitravatinib demonstrate encouraging results SAN DIEGO , Oct. 21, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology
View HTML
Toggle Summary Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call
- Two oral presentations will feature updated clinical data from an ongoing phase 2 clinical trial of sitravatinib in combination with nivolumab and a Phase 1b clinical trial of sitravatinib as a single agent - Proffered Paper Sessions (oral presentations) will include additional clinical trial
View HTML
Toggle Summary Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference
SAN DIEGO , Aug. 29, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two panel discussions, at the 2018 Citi Biotech Conference in Boston . Charles M. Baum , M.D., Ph.D., President and Chief Executive Officer will
View HTML
Toggle Summary Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
SAN DIEGO , Aug. 16, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced that a KRAS G12C poster will be presented by scientists from Mirati and Array BioPharma at the 255 th American Chemical Society (ACS) National Meeting &
View HTML
Toggle Summary Mirati Therapeutics Reports Second Quarter Financial Results
SAN DIEGO , Aug. 1, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2018 . "In June we successfully completed a financing, with net proceeds of $130.7 million ,
View HTML
Toggle Summary Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress
SAN DIEGO , July 24, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that two abstracts highlighting data from ongoing clinical studies of sitravatinib will be presented as Proffered Papers in oral presentations at the 2018
View HTML